Apexigen adds to Chinese antibody alliances with Duyiwei deal
This article was originally published in Scrip
Executive Summary
In a deal indicative of Chinese firms' growing interest in novel biologics, the privately held US antibody venture Apexigen has licensed a product with potential in oncology to Gansu Duyiwei Biological Pharmaceutical for development and commercialisation in China.